Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Apr
05
Today In Oncology
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors
Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo